Stocktwits on MSN
CLRB stock surged 27% today – here’s why retail is bullish about Cellectar’s blood cancer trial data
The study showed a major response rate of 61.8%, meeting its primary endpoint. ・The company is preparing for potential ...
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At ...
Detailed price information for Cellectar Biosciences Inc (CLRB-Q) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN
Cellectar Biosciences (CLRB) upgraded to buy: Here's what you should know
Cellectar Biosciences, Inc. (CLRB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our ...
On Tuesday, Cellectar Biosciences, Inc. (NASDAQ:CLRB) unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets ...
CELLECTAR BIOSCIENCES ($CLRB) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.01 per share, beating estimates of -$0. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results